Your browser doesn't support javascript.
loading
When to suspect infantile hypercalcemia-1?
Brancatella, A; Cappellani, D; Pierotti, L; Dinoi, E; Sardella, C; Borsari, S; Piaggi, P; Baldinotti, F; Caligo, M A; Marcocci, C; Cetani, F.
Afiliación
  • Brancatella A; Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy.
  • Cappellani D; Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy.
  • Pierotti L; Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy.
  • Dinoi E; Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy.
  • Sardella C; Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy.
  • Borsari S; Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy.
  • Piaggi P; Department of Information Engineering, University of Pisa, Pisa, Italy.
  • Baldinotti F; Endocrine Unit 2, Laboratory of Molecular Genetics, University Hospital of Pisa, Via Paradisa 2, 56124, Pisa, Italy.
  • Caligo MA; Endocrine Unit 2, Laboratory of Molecular Genetics, University Hospital of Pisa, Via Paradisa 2, 56124, Pisa, Italy.
  • Marcocci C; Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy.
  • Cetani F; Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy. cetani@endoc.med.unipi.it.
J Endocrinol Invest ; 2024 Feb 08.
Article en En | MEDLINE | ID: mdl-38329607
ABSTRACT

PURPOSE:

The screening test to suspect infantile hypercalcemia-1 (HCINF1) is the measure of 25(OH)D3/24,25(OH)2D3 ratio at mass spectroscopy (MS). When the ratio is > 80, the gold standard for the diagnosis is genetic analysis. Given its limited availability, MS may not represent a screening test and most cases of HCINF1 remain undiagnosed. Aim of the study is to identify cut-offs of serum calcium and PTH useful to suspect patients with HCINF1.

METHODS:

We compared the levels of total serum calcium and PTH of 6 patients with HCINF1 harboring biallelic CYP24A1 pathogenic variants with 3 different control groups (1) 12 subjects wild type for CYP24A1; (2) 12 subjects matched for age and sex; (3) 12 subjects matched for vitamin D levels. We validated the cut-offs, testing the number of adult patients affected by HCINF1 reported in the literature that could be identified using these cut-offs.

RESULTS:

A serum calcium level > 9.6 mg/dL showed the highest sensitivity (100%) and specificity (91%) in the comparison between homozygous and wild-type subjects. A serum PTH index < 0.315 showed the highest sensitivity (100%) and specificity (83.3%). A serum calcium level > 9.6 mg/dL was able to identify all adult HCINF1 patients whereas a PTH ratio < 0.315 identified 89.8% of the cases. Superimposable results were obtained using the other control groups.

CONCLUSION:

Patients with serum calcium levels higher than 9.6 mg/dL and a PTH index lower than 0.315 are likely to be affected by HCINF1. Their diagnosis may be confirmed using MS and genetic analysis.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: J Endocrinol Invest Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: J Endocrinol Invest Año: 2024 Tipo del documento: Article